9 Meters Biopharma (NMTR) Stock Analysis

What 9 Meters Biopharma does

Based in Raleigh, North Carolina, 9 Meters Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. Its core mission is to innovate treatments for individuals suffering from rare digestive conditions, gastrointestinal disorders with inadequate therapeutic options, and other severe debilitating ailments. The company's pipeline features several promising drug candidates. Larazotide, an 8-amino acid peptide, is currently in a Phase 3 clinical trial for the treatment of celiac disease and is also being assessed in a Phase IIa study for multi-system inflammatory syndrome. Another key asset, Vurolenatide, a long-acting injectable glucagon-like peptide-1, is undergoing Phase 2 clinical trials to address short bowel syndrome. Additionally, 9 Meters Biopharma is advancing other compounds, including NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended for the prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody designed to target specific obesity disorders; and NM-004, a double-cleaved mesalamine combined with an immunomodulator, slated for rare and/or orphan indications.

Key metrics

ETFs linked to NMTR

Broad-market and Healthcare sector ETFs an investor holding 9 Meters Biopharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NMTR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for 9 Meters Biopharma?

9 Meters Biopharma trades under the ticker NMTR on NASDAQ.

Which exchange is NMTR listed on?

NMTR is listed on NASDAQ.

What sector does 9 Meters Biopharma operate in?

9 Meters Biopharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NMTR in a portfolio?

PortView shows NMTR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.